124 related articles for article (PubMed ID: 8205258)
1. Effect of octreotide on glucose tolerance in acromegaly.
Koop BL; Harris AG; Ezzat S
Eur J Endocrinol; 1994 Jun; 130(6):581-6. PubMed ID: 8205258
[TBL] [Abstract][Full Text] [Related]
2. Glucose homeostasis in acromegaly: effects of long-acting somatostatin analogues treatment.
Baldelli R; Battista C; Leonetti F; Ghiggi MR; Ribaudo MC; Paoloni A; D'Amico E; Ferretti E; Baratta R; Liuzzi A; Trischitta V; Tamburrano G
Clin Endocrinol (Oxf); 2003 Oct; 59(4):492-9. PubMed ID: 14510913
[TBL] [Abstract][Full Text] [Related]
3. Deterioration of glycemic control during octreotide LAR treatment in an acromegalic Japanese patient with type 2 diabetes mellitus.
Kahara T; Ueno K; Torita M; Usuda R; Abe T
Endocr J; 2007 Apr; 54(2):329-33. PubMed ID: 17339747
[TBL] [Abstract][Full Text] [Related]
4. Glycemic profile in patients with acromegaly treated with somatostatin analogue.
Valea A; Carsote M; Ghervan C; Georgescu C
J Med Life; 2015; 8 Spec Issue(Spec Issue):82-6. PubMed ID: 26361517
[TBL] [Abstract][Full Text] [Related]
5. Short-term effects of octreotide on glucose tolerance in patients with acromegaly.
Sato K; Takamatsu K; Hashimoto K
Endocr J; 1995 Dec; 42(6):739-45. PubMed ID: 8822314
[TBL] [Abstract][Full Text] [Related]
6. [Current alternative in the pharmacotherapy of acromegaly: the long-acting somatostatin analogue octreotide].
Laczi F; Magony S; Julesz J
Orv Hetil; 2002 May; 143(19 Suppl):1062-6. PubMed ID: 12063861
[TBL] [Abstract][Full Text] [Related]
7. Effects of long-acting release octreotide on glucose homeostasis in acromegaly patients after trans-sphenoidal surgery.
Chen HS; Wu TE; Jap TS; Hsiao LC; Lin HD; Lee SH; Lin SH
Horm Metab Res; 2011 Jun; 43(6):433-9. PubMed ID: 21538290
[TBL] [Abstract][Full Text] [Related]
8. [Evaluation of glucose metabolism in acromegalic patients before and after treatment with octreotide LAR].
Correa LL; Taboada GF; Van Haute FR; Casini AF; Balarini GA; Vieira Neto L; Machado Ede O; Fontes R; Andrade CC; Schrank Y; Gadelha MR
Arq Bras Endocrinol Metabol; 2008 Feb; 52(1):55-64. PubMed ID: 18345397
[TBL] [Abstract][Full Text] [Related]
9. Effects of treatment with octreotide in acromegalic patients--a multicenter Italian study. Italian Multicenter Octreotide Study Group.
Arosio M; Macchelli S; Rossi CM; Casati G; Biella O; Faglia G
Eur J Endocrinol; 1995 Oct; 133(4):430-9. PubMed ID: 7581966
[TBL] [Abstract][Full Text] [Related]
10. Impact of octreotide, a long-acting somatostatin analogue, on glucose tolerance and insulin sensitivity in acromegaly.
Ho KK; Jenkins AB; Furler SM; Borkman M; Chisholm DJ
Clin Endocrinol (Oxf); 1992 Mar; 36(3):271-9. PubMed ID: 1563080
[TBL] [Abstract][Full Text] [Related]
11. Dose-response study and long term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly.
Quabbe HJ; Plöckinger U
J Clin Endocrinol Metab; 1989 May; 68(5):873-81. PubMed ID: 2565912
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic efficacy of the somatostatin analog SMS 201-995 (octreotide) in acromegaly. Effects of dose and frequency and long-term safety.
Ho KY; Weissberger AJ; Marbach P; Lazarus L
Ann Intern Med; 1990 Feb; 112(3):173-81. PubMed ID: 2404445
[TBL] [Abstract][Full Text] [Related]
13. Serum ghrelin levels in acromegaly: effects of surgical and long-acting octreotide therapy.
Freda PU; Reyes CM; Conwell IM; Sundeen RE; Wardlaw SL
J Clin Endocrinol Metab; 2003 May; 88(5):2037-44. PubMed ID: 12727951
[TBL] [Abstract][Full Text] [Related]
14. Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of the International Multicenter Acromegaly Study Group.
Vance ML; Harris AG
Arch Intern Med; 1991 Aug; 151(8):1573-8. PubMed ID: 1872661
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance.
Colao A; Pivonello R; Auriemma RS; De Martino MC; Bidlingmaier M; Briganti F; Tortora F; Burman P; Kourides IA; Strasburger CJ; Lombardi G
Eur J Endocrinol; 2006 Mar; 154(3):467-77. PubMed ID: 16498061
[TBL] [Abstract][Full Text] [Related]
16. A patient with acromegaly who showed remarkable improvement of hyperglycemia after treatment with octreotide.
Hirose T; Kuroda T; Otsuki M; Takagi M; Yamamoto H; Motomura T; Kurebayashi S; Miyashita Y; Koga M; Arita N; Hayakawa T; Kishimoto T; Kasayama S
Intern Med; 1997 May; 36(5):345-50. PubMed ID: 9213172
[TBL] [Abstract][Full Text] [Related]
17. Glucose tolerance during long term treatment with a somatostatin analogue.
Verschoor L; Lamberts SW; Uitterlinden P; Del Pozo E
Br Med J (Clin Res Ed); 1986 Nov; 293(6558):1327-8. PubMed ID: 2878704
[TBL] [Abstract][Full Text] [Related]
18. Carbohydrate tolerance and serum lipids in acromegaly before and during treatment with high dose octreotide.
James RA; Møller N; Chatterjee S; White M; Kendall-Taylor P
Diabet Med; 1991 Jul; 8(6):517-23. PubMed ID: 1832350
[TBL] [Abstract][Full Text] [Related]
19. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.
Resmini E; Minuto F; Colao A; Ferone D
Acta Diabetol; 2009 Jun; 46(2):85-95. PubMed ID: 19322513
[TBL] [Abstract][Full Text] [Related]
20. Additional metabolic effects of adding GH receptor antagonist to long-acting somatostatin analog in patients with active acromegaly.
Jawiarczyk A; Kałuzny M; Bolanowski M; Bednarek-Tupikowska G
Neuro Endocrinol Lett; 2008 Aug; 29(4):571-6. PubMed ID: 18766168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
